FRA:PFE • US7170811035
The current stock price of PFE.DE is 23.555 EUR. Today PFE.DE is up by 0.3%. In the past month the price increased by 0.19%. In the past year, price decreased by -0.55%.
ChartMill assigns a technical rating of 8 / 10 to PFE.DE. When comparing the yearly performance of all stocks, PFE.DE turns out to be only a medium performer in the overall market: it outperformed 44.92% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to PFE.DE. There are concerns on the financial health of PFE.DE while its profitability can be described as average.
On February 3, 2026 PFE.DE reported an EPS of 0.66 and a revenue of 17.56B. The company beat EPS expectations (14.29% surprise) and beat revenue expectations (2.56% surprise).
35 analysts have analysed PFE.DE and the average price target is 24.89 EUR. This implies a price increase of 5.66% is expected in the next year compared to the current price of 23.555.
For the next year, analysts expect an EPS growth of -7.56% and a revenue growth -1.41% for PFE.DE
Over the last trailing twelve months PFE.DE reported a non-GAAP Earnings per Share(EPS) of 2.79. The EPS increased by 3.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.42% | ||
| ROA | 3.73% | ||
| ROE | 8.99% | ||
| Debt/Equity | 0.71 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 8.97 | 184.165B | ||
| SNW | SANOFI | 8.97 | 183.755B | ||
| 1SAN | SANOFI | 8.96 | 183.392B | ||
| UCB | UCB SA | 25.12 | 49.367B | ||
| UNC | UCB SA | 24.65 | 49.308B | ||
| MRK | MERCK KGAA | 13.38 | 48.261B | ||
| 1MRK | MERCK KGAA | 12.9 | 48.217B | ||
| BAYN | BAYER AG-REG | 8.4 | 39.311B | ||
| 1BAYN | BAYER AG-REG | 8.55 | 39.311B | ||
| IPN | IPSEN | 12.79 | 13.091B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.681B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.22 | 9.666B | ||
| VIRP | VIRBAC SA | 15.71 | 2.844B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
IPO: 1944-01-17
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK US
Employees: 75000
Phone: 13026587581
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
The current stock price of PFE.DE is 23.555 EUR. The price increased by 0.3% in the last trading session.
PFIZER INC (PFE.DE) has a dividend yield of 6.46%. The yearly dividend amount is currently 1.49.
PFE.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
PFIZER INC (PFE.DE) operates in the Health Care sector and the Pharmaceuticals industry.
The PE ratio for PFIZER INC (PFE.DE) is 8.44. This is based on the reported non-GAAP earnings per share of 2.79 and the current share price of 23.555 EUR.
PFIZER INC (PFE.DE) will report earnings on 2026-04-27.